AACR-2016 Clinical Trial Post #2: CFI-400945
Clinical trial abstracts of the AACR meeting next week were released this afternoon. AACR presents some clinical trial results - the ASCO conference in June presents much more. A lot of eyes will be on the PD1/Avastin/FOLFOX trial results which will be presented on Monday to see if they mention MSS-CRC. Once I hear feedback what was said, I'll post next week on that one.
Today I'll post (3) clinical trial poster abstracts I noticed with CRC data and with currently open trials.
Title: First-in-human phase I trial of the oral PLK4 inhibitor CFI-400945 in patients with advanced solid tumors
Open Trial: https://clinicaltrials.gov/ct2/show/NCT ... 945&rank=1
Mechanism: oral PLK4 inhibitor (targeted agent)
CRC Data: Two patients enrolled at the 48 mg dose level have completed >6 cycles, including a patient with KRAS mutant colorectal cancer who achieved 24% reduction in target lesions and >50% reduction in serum CEA levels.
Side effects: Some chemo-type side effects
Full abstract: http://www.abstractsonline.com/plan/Vie ... 0fb1922267